Melissa Sgodzai, PhD
Stephan Winklmeier, PhD
Effect of IVIG on autoreactive B Cells: Insights from paediatric and adult myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD)
Fabian Szepanowski, PhD
Exploring the Relationship Between IVIg and Lysophosphatidic Acid (LPA) as Potential Biomarker in Chronic Inflammatory Demyelinating Polyneuropathy
Roberto Bellanti, MBBS MRCP AFHEA
Peripheral nerve specific biomarkers and in vitro models of neuropathy for the evaluation of IVIg treatment response and dependency
Jonathan Morena, DO.
Effects of intravenous immunoglobulin on myeloid cell function in Guillain-Barré syndrome
Jeremie Martinet, PharmD, PhD
Immunoglobulins for neuromuscular disorders: immunomodulation and myoregeneration by IVIg in immune-mediated necrotising myopathy (myoRIg)
Luuk Wieske, MD, PhD
Serum nerve damage biomarkers for disease activity in IVIg treated patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
Dr. med. Miriam Fichtner
IVIG influence on pathogenic B cells in myasthenia gravis
Ruth Huizinga, PhD
Effect of IVIg on the B-cell receptor repertoire of patients with the Guillain-Barré syndrome
Luis Querol, MD, PhD
IVIg effects on regulatory B cells in patients with neuroimmune diseases
Krista Kuitwaard, MD
Genetic biomarkers associated with IVIg treatment response or dependency in CIDP
Bart C. Jacobs, PhD, MD
Fcγ-receptor gene polymorphisms and the pharmacokinetics of immunoglobulin treatment in the Guillain-Barré syndrome
Gerd Meyer zu Hörste, MD
Immunoglobulins in a new animal model of CIDP – the spontaneous chronic autoimmune neuritis in ICAM-1 deficient NOD mice